Does Modulation of an Epigenetic Clock Define a Geroprotector?

Area of Science:

• Gerontology
• Clinical Trial Design
• Biomarkers of Aging

Background:

• Growing interest in interventions (geroprotectors) to enhance healthspan and lifespan.
• Challenges exist in clinically validating the efficacy of geroprotectors.
• Defining 'geroprotector' and appropriate trial endpoints is crucial.

Purpose of the Study:

• Discuss key issues in designing and interpreting clinical trials for geroprotectors.
• Evaluate the role of surrogate endpoints like epigenetic clocks.
• Highlight the need for studies linking epigenetic clocks to disease and geroprotector efficacy.

Main Methods:

• Review of challenges in geroprotector clinical trial design.
• Discussion on the definition and validation of geroprotectors.
• Analysis of epigenetic clocks as potential surrogate endpoints.

Main Results:

• Clinical validation of geroprotectors presents significant design and interpretation challenges.
• Epigenetic clocks are emerging surrogate endpoints, but their relationship with health is complex.
• Current understanding necessitates further research into epigenetic clocks and their correlation with disease processes.

Conclusions:

• Geroprotectors must demonstrate clear health and disease prevention benefits.
• The utility of epigenetic clocks as primary endpoints requires further scrutiny.
• Integrated studies are essential to advance the field of aging research and geroprotection.